Procedural steps taken after granting the Marketing Authorisation 
For procedures finalised after 1 December 2003 please refer to module 8B. 
• 
• 
• 
• 
• 
• 
• 
On  15  November  2000  the  Marketing  Authorisation  Holder  submitted  a  Type  II  Variation  in 
accordance  with  Commission  Regulation  (EC)  No.  542/95  as  amended.  This  variation  was 
submitted to demonstrate compliance with Commission Directive 1999/82/EC and the Note for 
Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents 
via Medicinal Products (CPMP/BWP/1230/98 rev.1) and provided scientific information, which 
was  then supplemented by a Certificate of Suitability issued  by the European  Pharmacopoeia. 
The  CPMP,  during  its  March  2001  plenary  meeting,  considered  the  variation  acceptable  and 
issued  on  29  March  2001  an  Opinion  on  the  Type  II  variation  to  the  Commission  Decision 
Authorisation of 29 September 2000, as amended. 
Pursuant  to  Article  4  of  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995  as 
amended, the MAH submitted to the EMEA on 15 November 2000 an application for a Type I 
variation for Keppra. The MAH applied to increase product capacity by increasing batch sizes 
in the synthesis of the active substance. The EMEA notified the European Commission that the 
above-mentioned variation was acceptable on 20 December 2000. 
Pursuant  to  Article  4  of  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995  as 
amended, the MAH submitted to the EMEA on 27 November 2000 an application for a Type I 
variation for Keppra. The MAH applied to update chemical and pharmaceutical documentation 
concerning  manufacturing  process  of  the  active  substance.  The  EMEA  notified  the  European 
Commission that the above-mentioned variation was acceptable on 20 December 2000.  
Pursuant  to  Article  4  of  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995  as 
amended, the MAH submitted to the EMEA on 27 November 2000 an application for a Type I 
variation for Keppra. The Marketing Authorisation Holder applied to update the chemical and 
pharmaceutical  documentation  in  order  to  increase  the  batch  size  of  intermediates  used  in  the 
active  substance  synthesis.  The  EMEA  notified  the  European  Commission  that  the  above-
mentioned variation was acceptable on 20 December 2000. 
Pursuant  to  Article  4  of  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995  as 
amended, the MAH submitted to the EMEA on 1 December 2000  an application for a Type I 
variation for Keppra. The Marketing Authorisation Holder applied to include an alternative site 
for the manufacture of intermediates used in the active substance synthesis. The EMEA notified 
the  European  Commission  that  the  above-mentioned  variation  was  acceptable  on  22  January 
2001. 
Pursuant  to  Article  4  of  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995  as 
amended, the MAH submitted to the EMEA on 15 December 2000 an application for a Type I 
variation  for  Keppra.  The  Marketing  Authorisation  Holder  applied  to  include  the  storage 
condition  ‘do  not  store  above  25°C.’  on  the  product  literature.  Minor  French  linguistic 
corrections  and  an  address  change  for  a  local  representative  in  the  package  leaflet  were 
proposed.  The  EMEA  notified  the  European  Commission  that  the  above-mentioned  variation 
was acceptable on 2 March 2001. The amended Commission Decision was issued on 27 April 
2001. 
Pursuant  to  Article  4  of  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995  as 
amended,  the  MAH  submitted  to  the  EMEA  on  3  January 2001  an  application  for  a  Type  I 
variation for Keppra. The Marketing Authorisation Holder applied to increase the batch size for 
the  intermediates  of  the  active  substance  synthesis.  The  EMEA  notified  the  European 
Commission that the above-mentioned variation was acceptable on 22 January 2001. 
1/4 
EMEA 2004 
 
 
 
 
 
 
 
 
 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Pursuant  to  Article  4  of  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995  as 
amended,  the  MAH  submitted  to  the  EMEA  on  3  January 2001  an  application  for  a  Type  I 
variation for Keppra. The Marketing Authorisation Holder applied for a change to the analytical 
method  used  for  the  analysis  of  a  starting  material.  The  EMEA  notified  the  European 
Commission that the above-mentioned variation was acceptable on 22 January 2001. 
Pursuant  to  Article  4  of  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995  as 
amended, the MAH submitted to the EMEA on 31 January 2001 applications for three Type I 
variations  for  Keppra.  The  Marketing  Authorisation  Holder  applied  for  changes  to  the  test 
procedure  for  the  finished  product.  The  EMEA  notified  the  European  Commission  that  the 
above-mentioned variations were acceptable on 7 March 2001. 
On  11  April  2001  the  Marketing  Authorisation  Holder  submitted  a  Type  II  Variation  in 
accordance  with  Commission  Regulation  (EC)  No.  542/95  as  amended.  This  variation  was 
submitted  to  introduce  a  new  alternative  route  of  synthesis  for  the  active  substance 
levetiracetam. The CPMP, during its September 2001 plenary meeting, considered the variation 
acceptable  and  issued  on  20  September  2001  an  Opinion  on  the  Type  II  variation  to  the 
Commission Decision Authorisation of 29 September 2000, as amended.  
Pursuant  to  Article  4  of  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995  as 
amended,  the  MAH  submitted  to  the  EMEA  on  18  October 2001  an  application  for  a  Type  I 
variation for Keppra. The Marketing Authorisation Holder applied for a change in supplier of an 
intermediate compound used in the manufacture of the active substance. The EMEA notified the 
European  Commission  that  the  above-mentioned  variations  were  acceptable  on  21  November 
2001. 
The  MAH  submitted  on  10  January  2002  a  request  to  introduce  changes  to  an  aspect  of  the 
labelling not connected to the SPC, in accordance with Article  61(3) of Council Directive No 
2001/83/EC. This change relates to addition of spaces and writing the abbreviation Exp in lower 
case  instead  of  capitals.  The  MAH  received  a  positive  notification  from  the  EMEA  on  5 
February 2002. 
Pursuant  to  Article  4  of  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995  as 
amended,  the  MAH  submitted  to  the  EMEA  on  8  February 2002  an  application  for  a  Type  I 
variation  for  Keppra.  The  Marketing  Authorisation  Holder  applied  for  a  minor  change  of 
manufacturing process of the active substance. The EMEA notified the European Commission 
that the above-mentioned variations were acceptable on 15 March 2002. 
Pursuant  to  Article  4  of  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995  as 
amended,  the  MAH  submitted  to  the  EMEA  on  11  April 2002  an  application  for  a  Type  I 
variation for Keppra. The Marketing Authorisation Holder applied for changes to comply with 
supplements to pharmacopoeias. The EMEA notified the European Commission that the above-
mentioned variations were acceptable on 15 March 2002. 
On 6 November 2001, the Marketing Authorisation Holder submitted an application for a Type 
II variation in accordance with Art. 6 of Commission Regulation (EC) No. 542/95, as amended. 
The  Marketing  Authorisation  Holder  applied  for  a  variation  to  update  the  SPC  following 
assessment of the second PSUR. The CPMP during its April 2002 plenary meeting considered 
the  variation  acceptable  and  issued  on  25  April  2002  a  positive  Opinion  on  the  Type  II 
variation. The corresponding Commission Decision was issued on 18 July 2002.  
Pursuant  to  Article  4  of  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995  as 
amended,  the  MAH  submitted  to  the  EMEA  on  14  August 2002  an  application  for  a  Type  I 
variation for Keppra. (EMEA/H/C//277I/21) The Marketing Authorisation Holder applied for a 
change  in  supplier  of  an  intermediate  compound  used  in  the  manufacture  of  the  active 
substance. The EMEA notified the European Commission that the above-mentioned variations 
were acceptable on 20 September 2002. 
2/4 
EMEA 2004 
 
 
 
 
 
 
 
 
 
• 
• 
• 
• 
• 
• 
• 
• 
Pursuant  to  Article  4  of  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995  as 
amended, the MAH submitted to the EMEA on 3 September 2002 an application for a Type I 
variation for Keppra. (EMEA/H/C/277/I/22) The Marketing Authorisation Holder applied for an 
addition  of  manufacturer  of  active  substance.  The  EMEA  notified  the  European  Commission 
that the above-mentioned variations were acceptable on 1 October 2002. 
Pursuant  to  Article  4  of  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995  as 
amended, the MAH submitted to the EMEA on 19 September 2002 an application for a Type I 
variation for Keppra (EMEA/H/C/277/I/23). The Marketing Authorisation Holder applied for a 
minor  change  of  manufacturing  process  of  the  active  substance.  The  EMEA  notified  the 
European  Commission  that  the  above-mentioned  variations  were  acceptable  on  18  October 
2002. 
Pursuant  to  Article  4  of  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995  as 
amended,  the  MAH  submitted  to  the  EMEA  on  03  October  2002  an  application  for  a  Type  I 
variation for Keppra (EMEA/H/C/277/I/24). The Marketing Authorisation Holder applied for a 
change of batch size of active substance. The EMEA notified the European Commission that the 
above-mentioned variations were acceptable on 25 October 2002. 
On 6 August 2002, the Marketing Authorisation Holder submitted an application for a Type II 
variation in  accordance with Art. 6  of Commission  Regulation (EC) No. 542/95, as amended, 
for a variation to update the SPC following assessment of the 3rd and 4th PSUR. In addition, the 
opportunity was taken to amend minor typographical errors and better reflect the initial analysis 
on preclinical safety data (EMEA/H/C/277/II/20). The CPMP during its October 2002 plenary 
meeting considered the variation acceptable and issued on 17 October 2002 a positive Opinion 
on  the  Type  II  variation.  The  corresponding  Commission  Decision  was  issued  on  14  January      
2003. 
Pursuant  to  Article  4  of  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995  as 
amended, the MAH submitted to the EMEA on 18 November 2002 an application for a Type I 
variation for Keppra (EMEA/H/C/277/I/25). The Marketing Authorisation Holder applied for an 
extension  of  shelf  life  as  foreseen  at  time  of  authorisation.  The  EMEA  notified  the  European 
Commission that the above-mentioned variations were acceptable on 17 January 2003. 
On  5  February  2002,  the  Marketing  Authorisation  Holder  submitted  an  application  for 
Marketing  Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products 
(EMEA) for Keppra 100 mg/ml Oral Solution under Annex II to Commission Regulation (EC) 
No. 542/95 as amended (EMEA/H/C/277/X/18). During the meeting on 19-21 November 2002 
the  CPMP,  in  the  light  of  the  overall  data  submitted  and  the  scientific  discussion  within  the 
Committee,  issued  a  positive  opinion  for  granting  a  Marketing  Authorisation  to  Keppra  100 
mg/ml  Oral  Solution  on  21  November  2002.  The  corresponding  Commission  Decision  was 
issued on 03 March 2003. 
On 10 December 2002, the Marketing Authorisation Holder submitted an application for a Type 
II variation in accordance with Art. 6 of Commission Regulation (EC) No. 542/95, as amended, 
for a variation to add an alternative manufacturing site for the active substance manufacturing 
process (EMEA/H/C/277/II/26). During the April 2003 meeting, the CPMP, adopted a positive 
opinion on the variation on 25 April 2003. The corresponding Commission Decision was issued 
on 02 May 2003. 
Pursuant  to  Article  4  of  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995  as 
amended,  the  MAH  submitted  to  the  EMEA  on  20  June  2003  an  application  for  a  Type  I 
variation  for  the  deletion  of  a  colouring  agent  from  the  coating  formulation  used  for  the  500 
mg.film-coated  tablets  (EMEA/H/C/277/I/27).  The  EMEA  notified  the  European  Commission 
that this variation was acceptable on 30 July 2003. 
3/4 
EMEA 2004 
 
 
 
 
 
 
 
 
 
 
• 
On  16  July  2003  the  Marketing  Authorisation  Holder  submitted  an  application  for  a  Type  II 
variation in  accordance with Art. 6  of Commission  Regulation (EC) No. 542/95, as amended, 
for a variation to add an alternative manufacturing site for the active substance manufacturing 
process (EMEA/H/C/277/II/28). The CPMP, during its November plenary meeting, considered 
the changes acceptable and issued on 20 November 2003 an Opinion on the Type II variation to 
the Community Marketing Authorisation. The corresponding Commission Decision was issued 
on 16 December 2003. 
4/4 
EMEA 2004 
 
 
 
